| Title | Bristols’ DLBCL CAR-T Therapy -Lisocabtagene Maraleucel (JCAR017)- Mellalta Meets Findings |
|---|
| URL | https://mellalta.com/bristols-dlbcl-car-t-therapy-lisocabtagene-maraleucel-jcar017-future-strategy-latest-events/ |
|---|
| Category | Fitness Health --> Disabilities and Disorders |
|---|
| Meta Keywords | liso-cel and JCAR017, Lisocabtagene maraleucel , CAART, CART therapy, CAAR T Cell, Autoimmune Disease, Bristol, EMA, Juno Therapeutics, Bristol |
|---|
| Meta Description | On July 17, 2020, Bristol’s liso-cel was validated for MAA by EMA for Relapsed or refractory (R/R) diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma and follicular lymphoma grade 3B. The Therapy is also under review by FDA |
|---|
| Owner | Emma Stones |
|---|
| Description |
|---|
| Lisocabtagene maraleucel, also known as liso-cel and JCAR017 is a 4-1BB-based second generation CAR-T therapy, that contains a distinct IgG4-based hinge. The therapy is a key pipeline asset which Bristol-Myers picked up through its takeover of Celgene, originally belongs to Juno Therapeutics. |
